A novel finding of phosphorylated (activated) VEGF in vitreous samples may present a new class of biomarkers for the treatment and management of AMD and other retinal disorders.
A novel finding of phosphorylated (activated) VEGF in vitreous samples may present a new class of biomarkers for the treatment and management of AMD and other retinal disorders.